Clicky

Endo International PLC(EO7)

Description: Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court


Keywords: Pharmaceutical Pharmaceutical Products Pain Pain Management U.S. Bankruptcy Court Transplantation Erectile Dysfunction Attention Deficit Hyperactivity Disorder Deficiency Testosterone Ophthalmic Products Prescription Products Hypogonadism Dupuytren's Contracture Central Precocious Puberty Ertapenem Xiaflex

Home Page: www.endo.com

Minerva House
Dublin, 4
Ireland
Phone: 353 1 268 2000


Officers

Name Title
Mr. Blaise A. Coleman Pres, CEO & Director
Mr. Mark T. Bradley Exec. VP & CFO
Mr. Matthew Joseph Maletta Exec. VP, Chief Legal Officer & Company Sec.
Mr. Patrick A. Barry Exec. VP & Pres of Global Commercial Operations
Frank B. Raciti VP, Controller & Chief Accounting Officer
Ms. Cheryl Stouch Sr. VP of Information Technology & Chief Information Officer
Ms. Laure E. Park Sr. VP of Investor Relations & Corp. Affairs
Ms. Susan Williamson Sr. VP & Chief Compliance Officer
Ms. Tracy Basso Chief HR Officer
Mr. James Papp Head of Endo Ventures Limited & Sr. VP of Global Supply Chain

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 1.4023
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 0.0071
IPO Date:
Fiscal Year End: December
Full Time Employees: 3103
Back to stocks